HHK001 not checked
Huahai Pharmaceutical (Huaota)
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a single subcutaneous injection of 3.75 mg HHK001 (investigational leuprorelin acetate preparation).”In the company’s words, NCT07755956 on ClinicalTrials.gov
- Tested for
- Endometriosis
- Main trialPhase 1
- “The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check how the body absorbs and responds to each medicine, monitor possible side effects and treatment benefits. Researchers will compare HHK001 to Enantone to test the advantages of its updated formulation.”In the company’s words, NCT07755956 on ClinicalTrials.gov
Other drugs for Endometriosis
- ElagolixAbbVie · Phase 3
- LinzagolixKissei Pharmaceutical Co., Ltd. · Phase 3
- HMI-115Hope Medicine (Nanjing) Co., Ltd · Phase 3
- RelugolixSumitomo Pharma America, Inc. · Phase 3
- VipoglanstatGesynta Pharma AB · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
Coming up1
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Mar 2027 | Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026